Ziv-aflibercept: a novel option for the treatment of polypoidal choroidal vasculopathy. (18th December 2015)

• Record Type: Journal Article
• Authors: Videkar, Chetan; Kapoor, Aditya; Chhablani, Jay; Narayanan, Raja
• Is Part Of: BMJ case reports. Volume 2015
• Publication Date: 2015-12-18
• Subjects: Medicine -- Case studies -- Periodicals; 610.5
• DOI: 10.1136/bcr-2015-212988
• Languages: English
• ISSNs: 1757-790X

Abstract

Abstract : Polypoidal choroidal vasculopathy (PCV) is an exudative maculopathy usually treated using photodynamic therapy (PDT) and antivascular endothelial growth factor agents. However, these cases may sometimes be refractory to both PDT and ranibizumab or bevacizumab, and may have persistent intra-retinal fluid. Recently, studies have reported that aflibercept may be effective in such resistant cases. However, high cost and limited availability has restricted its use to only a few countries. Ziv-aflibercept (Zaltrap), a systemic analogue of aflibercept, has been tried recently and it has been effective in macular oedema. We report a case of PCV resistant to PDT and ranibizumab, which responded well to intravitreal ziv-aflibercept.